BR0113331A - Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica - Google Patents

Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica

Info

Publication number
BR0113331A
BR0113331A BR0113331-4A BR0113331A BR0113331A BR 0113331 A BR0113331 A BR 0113331A BR 0113331 A BR0113331 A BR 0113331A BR 0113331 A BR0113331 A BR 0113331A
Authority
BR
Brazil
Prior art keywords
alpha
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
phenylalanine derivatives
Prior art date
Application number
BR0113331-4A
Other languages
English (en)
Other versions
BRPI0113331B8 (pt
BR0113331B1 (pt
Inventor
Shingo Makino
Tatsuya Okuzumi
Toshihiko Yoshimura
Yuko Satake
Nobuyasu Suzuki
Hiroyuki Izawa
Kazuyuki Sagi
Akira Chiba
Eiji Nakanisha
Masahiro Murata
Takashi Tsuji
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR0113331A publication Critical patent/BR0113331A/pt
Publication of BR0113331B1 publication Critical patent/BR0113331B1/pt
Publication of BRPI0113331B8 publication Critical patent/BRPI0113331B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE FENILALANINA OU SEUS SAIS FARMACEUTICAMENTE ACEITáVEIS, ANTAGONISTA DE INTEGRINA ALFA 4, AGENTE TERAPêUTICO OU AGENTE PREVENTIVO PARA DOENçAS INFLAMATóRIAS, E, COMPOSIçãO FARMACêUTICA". Derivados de fenilalanina especificados e seus análogos apresentam uma atividade antagonista para integrina <244>4. Eles são usados como agentes terapêuticos para várias doenças relativas à integrina <244>4.
BRPI0113331A 2000-08-18 2001-08-15 derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica BRPI0113331B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000248728 2000-08-18
JP2001147451 2001-05-17
PCT/JP2001/007039 WO2002016329A1 (en) 2000-08-18 2001-08-15 Novel phenylalanine derivatives

Publications (3)

Publication Number Publication Date
BR0113331A true BR0113331A (pt) 2004-02-25
BR0113331B1 BR0113331B1 (pt) 2017-11-14
BRPI0113331B8 BRPI0113331B8 (pt) 2021-05-25

Family

ID=26598103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0113331A BRPI0113331B8 (pt) 2000-08-18 2001-08-15 derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica

Country Status (27)

Country Link
US (4) US7153963B2 (pt)
EP (1) EP1288205B1 (pt)
JP (1) JP3440469B2 (pt)
KR (1) KR100675036B1 (pt)
CN (1) CN1325480C (pt)
AT (1) ATE497385T1 (pt)
AU (2) AU7874001A (pt)
BG (1) BG66085B1 (pt)
BR (1) BRPI0113331B8 (pt)
CA (1) CA2420040C (pt)
CZ (1) CZ302653B6 (pt)
DE (1) DE60143984D1 (pt)
DK (1) DK1288205T3 (pt)
HU (1) HU228914B1 (pt)
IL (2) IL154350A0 (pt)
MX (1) MXPA03001495A (pt)
NO (1) NO325738B1 (pt)
NZ (1) NZ524122A (pt)
PL (1) PL223152B1 (pt)
PT (1) PT1288205E (pt)
RU (1) RU2286340C2 (pt)
SI (1) SI1288205T1 (pt)
SK (1) SK287781B6 (pt)
TW (1) TWI229077B (pt)
UA (1) UA74385C2 (pt)
WO (1) WO2002016329A1 (pt)
YU (1) YU12203A (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
SK287781B6 (sk) * 2000-08-18 2011-09-05 Ajinomoto Co., Inc. Fenylalanínové deriváty, farmaceutický prípravok s ich obsahom a ich použitie
JP4895067B2 (ja) 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
WO2003010135A1 (en) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
AU2003211560A1 (en) * 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP1595870B1 (en) 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
CA2546115C (en) * 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
KR101123606B1 (ko) 2003-11-27 2012-03-20 아지노모토 가부시키가이샤 페닐알라닌 유도체의 결정 및 이의 제조방법
KR101194176B1 (ko) * 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
EP1765400A2 (en) * 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
WO2006137450A1 (ja) * 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用
EP1957476A1 (en) * 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200811164A (en) 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
CA2655573C (en) * 2006-06-19 2014-04-29 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
US7893046B2 (en) * 2006-06-20 2011-02-22 Toray Industries, Inc. Therapeutic or prophylactic agent for leukemia
CN101589028B (zh) * 2006-11-22 2014-02-19 味之素株式会社 具有喹唑啉二酮骨架的苯丙氨酸衍生物的制备方法及制备中间体
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102905707A (zh) 2010-03-29 2013-01-30 味之素株式会社 含有苯基丙氨酸衍生物的医药制剂
EP2853529A1 (en) * 2010-03-29 2015-04-01 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
JP6152093B2 (ja) * 2012-04-24 2017-06-21 Ｅａファーマ株式会社 スルホンアミド誘導体及びその医薬用途
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CN109867630A (zh) * 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
KR101806103B1 (ko) * 2013-10-29 2017-12-07 이에이 파마 가부시키가이샤 설폰아미드 유도체 및 이의 의약 용도
MX381440B (es) * 2014-09-29 2025-03-12 Ea Pharma Co Ltd Composicion farmaceutica para tratar colitis ulcerativa.
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP4732904A2 (en) 2015-10-06 2026-04-29 F. Hoffmann-La Roche AG Method for treating multiple sclerosis
CN108699008B (zh) 2016-02-05 2021-10-08 Ea制药株式会社 磺酰胺衍生物和含有其的药物组合物
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11963996B2 (en) * 2018-10-24 2024-04-23 Orthotrophix, Inc. Method of treating knee pain
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR20210098998A (ko) 2018-12-04 2021-08-11 오르토트로픽스 인코포레이티드 골관절염 치료시 사용하기 위한 제형
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
WO2022072156A1 (en) 2020-10-01 2022-04-07 Orthotrophix, Inc. Hard tissue therapeutics
WO2025058075A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 放射性陽電子放出核種炭素１１標識化合物、及び放射性組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2419928A1 (fr) * 1978-03-15 1979-10-12 Metabio Joullie Sa Nouveaux derives de la n-phenylalanine, leur preparation et leur application comme medicaments
DE4111394A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
HU914U (en) 1995-04-19 1996-10-28 Koevesi Machine tool for contour turning
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
PL338423A1 (en) 1997-07-31 2000-11-06 Elan Pharm Inc Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4
HUP0003921A3 (en) * 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
BR9811730B1 (pt) * 1997-08-22 2014-04-08 Hoffmann La Roche Derivados de n-aroilfenilalanina, uso dos mesmos, medicamentos contendo os mesmos.
CN1276785A (zh) 1997-08-22 2000-12-13 霍夫曼-拉罗奇有限公司 N－烷酰基苯丙氨酸衍生物
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (en) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
EP1233013B1 (en) * 1999-11-18 2007-02-28 Ajinomoto Co., Inc. Novel phenylalanine derivatives
RU2270193C2 (ru) 1999-12-06 2006-02-20 Ф.Хоффманн-Ля Рош Аг 4-пиридинил-n-ацил-l-фенилаланины
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
AU2224901A (en) * 1999-12-28 2001-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivatives
EP1270547A4 (en) * 2000-03-23 2005-07-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
SK287781B6 (sk) 2000-08-18 2011-09-05 Ajinomoto Co., Inc. Fenylalanínové deriváty, farmaceutický prípravok s ich obsahom a ich použitie
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
WO2003010135A1 (en) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
AU2003211560A1 (en) * 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP1595870B1 (en) * 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
KR101123606B1 (ko) * 2003-11-27 2012-03-20 아지노모토 가부시키가이샤 페닐알라닌 유도체의 결정 및 이의 제조방법
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
WO2006137450A1 (ja) 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用

Also Published As

Publication number Publication date
EP1288205B1 (en) 2011-02-02
YU12203A (sh) 2006-03-03
US20030220268A1 (en) 2003-11-27
NZ524122A (en) 2005-02-25
UA74385C2 (uk) 2005-12-15
DE60143984D1 (de) 2011-03-17
HUP0302997A3 (en) 2004-03-29
SI1288205T1 (sl) 2011-05-31
BG107555A (bg) 2003-09-30
CN1325480C (zh) 2007-07-11
JP3440469B2 (ja) 2003-08-25
BRPI0113331B8 (pt) 2021-05-25
AU7874001A (en) 2002-03-04
AU2001278740B9 (en) 2006-09-28
CA2420040C (en) 2009-02-03
PL361383A1 (en) 2004-10-04
RU2286340C2 (ru) 2006-10-27
US8222405B2 (en) 2012-07-17
IL154350A0 (en) 2003-09-17
US8426588B2 (en) 2013-04-23
US7153963B2 (en) 2006-12-26
SK1912003A3 (en) 2003-07-01
US20060223836A1 (en) 2006-10-05
PL223152B1 (pl) 2016-10-31
CZ302653B6 (cs) 2011-08-17
MXPA03001495A (es) 2003-06-06
KR20030048011A (ko) 2003-06-18
SK287781B6 (sk) 2011-09-05
NO325738B1 (no) 2008-07-14
CN1469867A (zh) 2004-01-21
AU2001278740B2 (en) 2006-04-06
BR0113331B1 (pt) 2017-11-14
US20120253041A1 (en) 2012-10-04
IL154350A (en) 2010-02-17
TWI229077B (en) 2005-03-11
HUP0302997A2 (hu) 2004-01-28
ATE497385T1 (de) 2011-02-15
US7872125B2 (en) 2011-01-18
CZ2003481A3 (cs) 2003-06-18
PT1288205E (pt) 2011-05-06
KR100675036B1 (ko) 2007-01-29
WO2002016329A1 (en) 2002-02-28
BG66085B1 (bg) 2011-03-31
NO20030744D0 (no) 2003-02-17
HU228914B1 (hu) 2013-06-28
EP1288205A1 (en) 2003-03-05
EP1288205A4 (en) 2007-05-23
DK1288205T3 (da) 2011-05-23
US20110065918A1 (en) 2011-03-17
NO20030744L (no) 2003-04-07
CA2420040A1 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR9912098A (pt) Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
DK1102579T3 (da) Medicinske aerosolformuleringer
SE9900961D0 (sv) Novel compounds
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
SE9802208D0 (sv) Novel compounds
TR200002481T2 (tr) Muskarinik Reseptör antegonistleri olarak 2-ariletil-(piperidin-4-ilmetil) amin türevleri
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
BR0012951A (pt) Agonistas de retinóides seletivos
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
SE0102055D0 (sv) New Compounds
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: EA PHARMA CO., LTD. (JP)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.